Clinical end point acceptance limit [Study As­sess­ment]

posted by PKS – India, 2019-04-05 11:17 (1904 d 07:32 ago) – Posting: # 20128
Views: 3,419

❝ ❝ Should I conclude bio-equivalence with the values of [-0.2025, 0.076] in clinical end point study. Can I assume it as within the interval of (-0.20, 0.20)


❝ What does your protocol say on exactly that matter?


My protocol says within (-0.20 and 0.20)

Complete thread:

UA Flag
Activity
 Admin contact
23,059 posts in 4,841 threads, 1,665 registered users;
29 visitors (0 registered, 29 guests [including 6 identified bots]).
Forum time: 18:50 CEST (Europe/Vienna)

[…] an inappropriate study design is incapable of answering
a research question, no matter how careful the subsequent
methodology, conduct, analysis, and interpretation:
Flawless execution of a flawed design achieves nothing worthwhile.    J. Rick Turner

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5